Guggenheim analyst Michael Schmidt initiates coverage on Enliven Therapeutics (NASDAQ: ELVN) with a Buy rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage